Skip to main content
OpenTrials
Completed

NCT Number: NCT06107439

Impact of Lipodystrophy on the Inflammatory State of Non-diabetic Dunnigan Reunion Island Subjects

Few data and small numbers affect the inflammatory profile of Dunnigan patients. The levels of certain pro-inflammatory biomarkers would be found higher in these subjects compared to control individuals. However, in these studies, several confounding factors were not taken into account such as smoking, an underlying chronic inflammatory disease such as diabetes and could limit the interpretation of the results. There is no other observation of the anti-inflammatory status of these patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Lipodystrophy Congenital, Hereditary, and Neonatal Diseases and Abnormalities Dunnigan Syndrome Genetic Diseases, Inborn Laminopathies Lipid Metabolism Disorders Lipid Metabolism, Inborn Errors Lipodystrophy, Familial Partial Metabolic Diseases Nutritional and Metabolic Diseases Skin Diseases Skin Diseases, Metabolic Skin and Connective Tissue Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

CHU La Réunion DRCI

Saint-Pierre, 97400, Reunion

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult subject (>18 years old) affected by partial Dunnigan lipodystrophy in the homozygous or heterozygous state (genetic search for the positive mutation carried out before inclusion in the study).
  • Person affiliated to or beneficiary of a social security scheme.
  • Free, informed and written consent signed by the participant and the investigator.

Exclusion criteria

  • - Minor
  • Persons placed under judicial protection, person participating in another research including a period of exclusion still in progress, severely impaired physical and/or psychological health, which, according to the investigator, may affect the participant's compliance with the study
  • Previous known diabetes
  • Pregnant woman
  • Woman who gave birth less than 6 months ago
  • Breastfeeding in progress
  • Participation in other research that may have an impact on the evaluation of the main judgment criteria
  • Hemoglobin b level < 7 mg/dl or < 9-10 mg/dl for patients with cardiovascular or respiratory pathology.
  • Proven inflammatory pathologies
  • Anti-inflammatory treatment: taking corticosteroids in the last 3 months.
  • Active smoking

Treatment and study plan

Bood and urine sampling

Biological

Bood and urine sampling

Primary outcomes

  1. pro-inflammatory markers

    Time frame: inclusion day

    blood sample and dosage of pro inflammatory cytokine

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire de la Réunion

Other

Registry information

Acronym: LIPOKINES

Important dates

Study start
2023
Primary completion
2025
Study completion
2025
First posted
Oct 30, 2023
Registry last updated
Sep 16, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.